Category Archives: Hepatitis C

Malaysian CL on Hep C drug reignites discussion in India

Source: The Hindu BusinessLine MUMBAI, OCTOBER 9:   Last month, Malaysia issued a compulsory licence (CL) on multinational drugmaker Gilead’s Hepatitis C drug Sofosbuvir for government use. This government action aimed at improving access to the drug in Malaysia has in fact … Continue reading

Posted in Compulsory Licensing, Hepatitis C, TRIPS flexibilities, Uncategorized | Leave a comment

DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C

[Kuala Lumpur, Geneva – 20 September 2017] Malaysia has issued a “government use” licence enabling access to more affordable versions of an expensive and patented medicine to treat hepatitis C. This landmark decision should help the more than 400,000 people living with … Continue reading

Posted in Compulsory Licensing, Hepatitis C, Uncategorized | Leave a comment

Delhi HC seeks AAP govt report on plea for free treatment of Hepatitis C

Source: PTI Published: Zee News A bench of Acting Chief Justice Gita Mittal and Justice C Hari Shankar also issued notice to the Delhi Government on the petition which sought direction to identify and publicise the names of hospitals, laboratories and medical … Continue reading

Posted in Drug prices, Drugs, Hepatitis C, Uncategorized | Tagged , | Leave a comment

Australian duo find global consumers for Indian generic drugs

By Divya Rajagopal, The Economic Times | May 23, 2017 MUMBAI: Remember Ron the rodeo cowboy from the Oscar-winning film Dallas Buyers Club? The biopic portrayed the story of Ron Woodroof, an AIDS patient in the mid-1980s who signed up … Continue reading

Posted in Generics, Hepatitis C, Sofosbuvir, Uncategorized | Leave a comment

Scaling up treatment of HCV in various Indian states

According to the WHO, India is a high burden country for HCV and has about 12-18 million chronically infected patients, most are unaware of their infection status and a third of whom will develop liver cirrhosis or hepatocellular carcinoma, which … Continue reading

Posted in Hepatitis C, Uncategorized | Leave a comment

Hepatitis drug patent application opposed

A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property’s Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair … Continue reading

Posted in Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Leave a comment

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment